Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation
Abstract Introduction Alzheimer’s disease (AD), a neurodegenerative disorder that progresses from mild cognitive impairment (MCI) to dementia, is responsible for significant burden on caregivers and healthcare systems. In this study, data from the large phase III CLARITY AD trial were used to estima...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2023-05-01
|
| Series: | Neurology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40120-023-00492-7 |
| _version_ | 1797555525868584960 |
|---|---|
| author | Ataru Igarashi Mie Kasai Azuma Quanwu Zhang Weicheng Ye Aditya Sardesai Henri Folse Ameya Chavan Kiyoyuki Tomita Amir Abbas Tahami Monfared |
| author_facet | Ataru Igarashi Mie Kasai Azuma Quanwu Zhang Weicheng Ye Aditya Sardesai Henri Folse Ameya Chavan Kiyoyuki Tomita Amir Abbas Tahami Monfared |
| author_sort | Ataru Igarashi |
| collection | DOAJ |
| description | Abstract Introduction Alzheimer’s disease (AD), a neurodegenerative disorder that progresses from mild cognitive impairment (MCI) to dementia, is responsible for significant burden on caregivers and healthcare systems. In this study, data from the large phase III CLARITY AD trial were used to estimate the societal value of lecanemab plus standard of care (SoC) versus SoC alone against a range of willingness-to-pay (WTP) thresholds from a healthcare and societal perspective in Japan. Methods A disease simulation model was used to evaluate the impact of lecanemab on disease progression in early AD based on data from the phase III CLARITY AD trial and published literature. The model used a series of predictive risk equations based on clinical and biomarker data from the Alzheimer’s Disease Neuroimaging Initiative and Assessment of Health Economics in Alzheimer’s Disease II study. The model predicted key patient outcomes, including life years (LYs), quality-adjusted life years (QALYs), and total healthcare and informal costs of patients and caregivers. Results Over a lifetime horizon, patients treated with lecanemab plus SoC gained an additional 0.73 LYs compared with SoC alone (8.50 years vs. 7.77 years). Lecanemab, with an average treatment duration of 3.68 years, was found to be associated with a 0.91 increase in patient QALYs and a total increase of 0.96 when accounting for caregiver utility. The estimated value of lecanemab varied according to the WTP thresholds (JPY 5–15 million per QALY gained) and the perspective employed. From the narrow healthcare payer’s perspective, it ranged from JPY 1,331,305 to JPY 3,939,399. From the broader healthcare payer’s perspective, it ranged from JPY 1,636,827 to JPY 4,249,702, while from the societal perspective, it ranged from JPY 1,938,740 to JPY 4,675,818. Conclusion The use of lecanemab plus SoC would improve health and humanistic outcomes with reduced economic burden for patients and caregivers with early AD in Japan. |
| first_indexed | 2024-03-10T16:49:47Z |
| format | Article |
| id | doaj.art-63339ccf91de43a0be5d3ab6d7555134 |
| institution | Directory Open Access Journal |
| issn | 2193-8253 2193-6536 |
| language | English |
| last_indexed | 2024-03-10T16:49:47Z |
| publishDate | 2023-05-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Neurology and Therapy |
| spelling | doaj.art-63339ccf91de43a0be5d3ab6d75551342023-11-20T11:21:42ZengAdis, Springer HealthcareNeurology and Therapy2193-82532193-65362023-05-011241133115710.1007/s40120-023-00492-7Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level SimulationAtaru Igarashi0Mie Kasai Azuma1Quanwu Zhang2Weicheng Ye3Aditya Sardesai4Henri Folse5Ameya Chavan6Kiyoyuki Tomita7Amir Abbas Tahami Monfared8Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of TokyoMedical Headquarter, Clinical Planning and Development, Eisai Co., Ltd.Global Alzheimer’s Disease and Brain Health, Eisai Inc.Evidence Synthesis, Modeling and Communication, Evidera Inc.Evidence Synthesis, Modeling and Communication, Evidera Inc.Evidence Synthesis, Modeling and Communication, Evidera Inc.Evidence Synthesis, Modeling and Communication, Evidera Inc.AD Value and Access Planning, Eisai Co., Ltd.Global Alzheimer’s Disease and Brain Health, Eisai Inc.Abstract Introduction Alzheimer’s disease (AD), a neurodegenerative disorder that progresses from mild cognitive impairment (MCI) to dementia, is responsible for significant burden on caregivers and healthcare systems. In this study, data from the large phase III CLARITY AD trial were used to estimate the societal value of lecanemab plus standard of care (SoC) versus SoC alone against a range of willingness-to-pay (WTP) thresholds from a healthcare and societal perspective in Japan. Methods A disease simulation model was used to evaluate the impact of lecanemab on disease progression in early AD based on data from the phase III CLARITY AD trial and published literature. The model used a series of predictive risk equations based on clinical and biomarker data from the Alzheimer’s Disease Neuroimaging Initiative and Assessment of Health Economics in Alzheimer’s Disease II study. The model predicted key patient outcomes, including life years (LYs), quality-adjusted life years (QALYs), and total healthcare and informal costs of patients and caregivers. Results Over a lifetime horizon, patients treated with lecanemab plus SoC gained an additional 0.73 LYs compared with SoC alone (8.50 years vs. 7.77 years). Lecanemab, with an average treatment duration of 3.68 years, was found to be associated with a 0.91 increase in patient QALYs and a total increase of 0.96 when accounting for caregiver utility. The estimated value of lecanemab varied according to the WTP thresholds (JPY 5–15 million per QALY gained) and the perspective employed. From the narrow healthcare payer’s perspective, it ranged from JPY 1,331,305 to JPY 3,939,399. From the broader healthcare payer’s perspective, it ranged from JPY 1,636,827 to JPY 4,249,702, while from the societal perspective, it ranged from JPY 1,938,740 to JPY 4,675,818. Conclusion The use of lecanemab plus SoC would improve health and humanistic outcomes with reduced economic burden for patients and caregivers with early AD in Japan.https://doi.org/10.1007/s40120-023-00492-7Alzheimer’s diseaseCost-effectivenessLecanemabCLARITY ADPatient-level simulatorQuality-adjusted life years |
| spellingShingle | Ataru Igarashi Mie Kasai Azuma Quanwu Zhang Weicheng Ye Aditya Sardesai Henri Folse Ameya Chavan Kiyoyuki Tomita Amir Abbas Tahami Monfared Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation Neurology and Therapy Alzheimer’s disease Cost-effectiveness Lecanemab CLARITY AD Patient-level simulator Quality-adjusted life years |
| title | Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation |
| title_full | Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation |
| title_fullStr | Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation |
| title_full_unstemmed | Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation |
| title_short | Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation |
| title_sort | predicting the societal value of lecanemab in early alzheimer s disease in japan a patient level simulation |
| topic | Alzheimer’s disease Cost-effectiveness Lecanemab CLARITY AD Patient-level simulator Quality-adjusted life years |
| url | https://doi.org/10.1007/s40120-023-00492-7 |
| work_keys_str_mv | AT ataruigarashi predictingthesocietalvalueoflecanemabinearlyalzheimersdiseaseinjapanapatientlevelsimulation AT miekasaiazuma predictingthesocietalvalueoflecanemabinearlyalzheimersdiseaseinjapanapatientlevelsimulation AT quanwuzhang predictingthesocietalvalueoflecanemabinearlyalzheimersdiseaseinjapanapatientlevelsimulation AT weichengye predictingthesocietalvalueoflecanemabinearlyalzheimersdiseaseinjapanapatientlevelsimulation AT adityasardesai predictingthesocietalvalueoflecanemabinearlyalzheimersdiseaseinjapanapatientlevelsimulation AT henrifolse predictingthesocietalvalueoflecanemabinearlyalzheimersdiseaseinjapanapatientlevelsimulation AT ameyachavan predictingthesocietalvalueoflecanemabinearlyalzheimersdiseaseinjapanapatientlevelsimulation AT kiyoyukitomita predictingthesocietalvalueoflecanemabinearlyalzheimersdiseaseinjapanapatientlevelsimulation AT amirabbastahamimonfared predictingthesocietalvalueoflecanemabinearlyalzheimersdiseaseinjapanapatientlevelsimulation |